People with neuromyelitis optica spectrum disorder (NMOSD) are at a nine times higher risk of developing autoimmune rheumatic diseases,…
Articles by Margarida Maia, PhD
Rituximab and mycophenolate mofetil (MMF) may be the most effective off-label options for neuromyelitis optica spectrum disorder (NMOSD) patients…
Treatment with Enspryng (satralizumab) allows nearly all neuromyelitis optica spectrum disorder (NMOSD) patients to remain free of relapses…
The platelet-to-lymphocyte ratio, a blood inflammatory marker that can be calculated based on the results of a simple blood test,…
People with neuromyelitis optica spectrum disorder (NMOSD) who test positive for self-reactive antibodies against the aquaporin 4 (AQP4) protein…
A predictive model based on laboratory and clinical risk factors for relapses in neuromyelitis optica spectrum disorder (NMOSD) was…
People with neuromyelitis optica spectrum disorder (NMOSD) have significantly higher levels of the signaling molecule CXCL13 in their blood…
BAT4406F, an experimental treatment in the pipeline of Bio-Thera Solutions, reduced the number of circulating immune B-cells that produce…
Early use of immunosuppressive therapy — when compared with a later treatment start — was associated with fewer relapses and…
A seaweed-derived preparation named GV-971 (sodium oligomannate) that has anti-inflammatory effects through the gut-brain axis, delayed the onset and progression…